ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-4)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02625480
Recruitment Status : Recruiting
First Posted : December 9, 2015
Last Update Posted : November 14, 2018
Sponsor:
Information provided by (Responsible Party):
Kite, A Gilead Company

Brief Summary:
The primary objectives of this study are to evaluate the safety and efficacy of KTE-C19 in pediatric and adolescent participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL).

Condition or disease Intervention/treatment Phase
Acute Lymphoblastic Leukemia Biological: KTE-C19 Drug: Fludarabine Drug: Cyclophosphamide Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-4)
Actual Study Start Date : February 1, 2016
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : October 2034


Arm Intervention/treatment
Experimental: Single Arm
A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR+ T cells/kg or 1 x 10^6 anti-CD19 CAR+ T cells/kg
Biological: KTE-C19
Drug: Fludarabine
Administered intravenously

Drug: Cyclophosphamide
Administered intravenously




Primary Outcome Measures :
  1. Phase 1: Percentage of Participants Experiencing Adverse Events Defined as Dose-Limiting Toxicities (DLT) [ Time Frame: Up to 28 days ]
    Dose-limiting toxicity is defined as protocol-defined KTE-C19-related events with onset within the first 28 days following KTE-C19 infusion.

  2. Phase 2: Overall Complete Remission Rate [ Time Frame: Up to 24 months ]
    Overall complete remission rate will be determined per independent review.


Secondary Outcome Measures :
  1. Duration of Remission [ Time Frame: Up to 24 months ]
    Duration of remission is defined as the time between the participant's first complete response per independent review to relapse or any death in the absence of documented relapse.

  2. Minimum Residual Disease Negative Remission Rate [ Time Frame: Up to 3 months ]
    Minimal residual disease (MRD) response rate is defined as MRD < 10^-4 per the standard assessment.

  3. Allogeneic Stem Cell Transplant Rate [ Time Frame: Up to 24 months ]
    The incidence of allogeneic stem cell transplant will be analyzed.

  4. Overall Survival [ Time Frame: Up to 15 years ]
    Overall survival is defined as the time from KTE-C19 infusion to the date of death from any cause.

  5. Relapse-Free Survival [ Time Frame: Up to 24 months ]
    Relapse-Free Survival is defined as the time from the KTE-C19 infusion date to the date of disease relapse or death from any cause.

  6. Percentage of Participants Experiencing Treatment-Emergent Adverse Events [ Time Frame: Up to 15 years ]
  7. Percentage of Participants Experiencing Common Terminology Criteria for Adverse Events (CTCAE) Grade Changes in Safety Laboratory Values [ Time Frame: Up to 15 years ]
  8. Percentage of Participants with Anti-KTE-C19 Antibodies [ Time Frame: Up to 15 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   2 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Relapsed or refractory B-precursor ALL defined as one of the following:

    • Primary refractory disease
    • Relapsed or refractory disease after 2 or more lines of systemic therapy
    • Relapsed or refractory disease after allogeneic transplant provided individual is at least 100 days from stem cell transplant at the time of enrollment
  • Morphological disease in the bone marrow (> 5% blasts)
  • Individuals with Ph+ disease are eligible if they are intolerant to tyrosine kinase inhibitor (TKI) therapy, or if they have relapsed/refractory disease despite treatment with at least 2 different TKIs
  • Ages 2 to 21 at the time of Assent or Consent per institutional review board (IRB) guidelines
  • Lansky (age < 16 years at the time of assent/consent) or Karnofsky (age ≥ 16 years at the time of assent/consent) performance status ≥ 80 at screening
  • Adequate renal, hepatic, pulmonary and cardiac function defined as:

    • Creatinine clearance ≥ 60 cc/min
    • Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 5 x upper limit of normal (ULN)
    • Total bilirubin ≤ 1.5 x ULN, except in individuals with Gilbert's syndrome
    • Left ventricular shortening fraction (LVSF) ≥ 30% or left ventricular ejection fraction (LVEF) ≥ 50%, no evidence of pericardial effusion as determined by an echocardiogram, and no clinical significant arrhythmias
    • No clinically significant pleural effusion
    • Baseline oxygen saturation > 92% on room air

Key Exclusion Criteria

  • Diagnosis of Burkitt's leukemia/lymphoma according to the World Health Organization (WHO) classification or chronic myelogenous leukemia lymphoid blast crisis
  • History of malignancy other than non-melanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) unless disease free for at least 3 years
  • History of severe hypersensitivity reaction to aminoglycosides or any of the agents used in this study
  • Presence of central nervous system (CNS)-3 disease and CNS-2 disease with neurological changes
  • History of concomitant genetic syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman-Diamond syndrome or any other known bone marrow failure syndrome
  • History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment
  • History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of enrollment.
  • Primary immunodeficiency
  • Known infection with HIV, hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV positive)
  • Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management.
  • Prior medication:

    • Prior CD19 directed therapy, including CAR+ T cell, BiTE, and antibody drug conjugate (ADC), with the exception of individuals who received KTE-C19 in this study and are eligible for re-treatment
    • Treatment with alemtuzumab within 6 months prior to leukapheresis, or treatment with clofarabine or cladribine within 3 months prior to leukapheresis
    • Donor lymphocyte infusion (DLI) within 28 days prior to enrollment
    • Any drug used for graft-versus-host disease (GVHD) within 4 weeks prior to enrollment
  • Acute GVHD grade II-IV by Glucksberg criteria or severity B-D by IBMTR index; acute or chronic GVHD requiring systemic treatment within 4 weeks prior to enrollment
  • Live vaccine ≤ 6 weeks prior to start of conditioning regimen
  • Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant. Females who have undergone surgical sterilization are not considered to be of childbearing potential
  • Individuals of both genders of child-bearing potential who are not willing to practice birth control from the time of consent through 6 months after the completion of KTE-C19

Note: Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02625480


Contacts
Contact: Medical Information 844-454-KITE medinfo@kitepharma.com

  Show 21 Study Locations
Sponsors and Collaborators
Kite, A Gilead Company
Investigators
Study Director: Kite Study Director Kite, A Gilead Company

Responsible Party: Kite, A Gilead Company
ClinicalTrials.gov Identifier: NCT02625480     History of Changes
Other Study ID Numbers: KTE-C19-104
2015-005010-30 ( EudraCT Number )
First Posted: December 9, 2015    Key Record Dates
Last Update Posted: November 14, 2018
Last Verified: November 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Cyclophosphamide
Fludarabine phosphate
Fludarabine
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antimetabolites, Antineoplastic
Antimetabolites